Scope, Claims, and U.S. Patent Landscape for Drug 10,588,988
United States patent 10,588,988 is directed to a workflow for producing lipid-encapsulated gas microspheres (lipid-encapsulated UCAs) for ultrasound imaging by using a shaking device with vial identification, where the device reads an indicator on the vial and then selects pre-set activation parameters (shaking rate and duration) that differ for aqueous vs non-aqueous UCA lipid formulations. The claims tightly couple: (i) specific lipid composition (DPPA, DPPC, MPEG5000-DPPE), (ii) solvent system differences (aqueous solvent vs propylene glycol/glycerol non-aqueous solvent with <5% water w/w), and (iii) activation defined by shaking motions at rates in the ~4000 to 5000+ motions per minute range and durations of at least 30 seconds (with multiple claim-dependent lock-ins to ~45 seconds, ~75 seconds).
What is the core inventive concept in 10,588,988?
The claims establish a controlled activation method that is conditional on formulation identity:
- The device reads an indicator on a vial (claim 1 and claim set 27-28) using a detector selected from:
- RFID reader/detector
- barcode scanner
- color scanner
- microchip reader
- Based on the read indicator (and optionally a lookup table), the system distinguishes:
- non-aqueous UCA lipid formulation vs aqueous UCA lipid formulation
- The processor then selects different pre-set activation parameters:
- activation includes imparting a shaking pattern using the device
- duration is generally constrained to at least 30 seconds
- shaking rate is generally constrained to at least 3000 for non-aqueous and ≥4000 in claim 2 and claim 7/8
- After activation, the method includes:
- administering the lipid-encapsulated gas microspheres to a subject
- obtaining an ultrasound image of the subject
The claims also define a specific chemistry envelope:
- Aqueous UCA lipid formulation: DPPA, DPPC, MPEG5000-DPPE in an aqueous solvent, plus gas
- Non-aqueous UCA lipid formulation: DPPA, DPPC, MPEG5000-DPPE in a non-aqueous solvent comprising propylene glycol and glycerol, plus gas, with <5% water (w/w)
Composition-and-activation linkage (where scope is won or lost)
The independent claim 1 requires all of the following simultaneously:
- UCA lipid formulation identification via indicator + detector
- Different activation parameter sets for aqueous vs non-aqueous
- Non-aqueous formulation solvent constraints: propylene glycol + glycerol; <5% water (w/w)
- Lipid composition constraints: DPPA, DPPC, MPEG5000-DPPE
- Activation via shaking device with pre-set options including duration ≥30 seconds
- Downstream use: administer microspheres and obtain ultrasound image
Dependent claims then tighten the mechanical and parameter envelope.
How do the claim set boundaries define infringement risk?
1) Independent claim 1: broadest anchor plus several tight chemistry/parameter couplings
Independent claim 1 requires:
- Detector: RFID reader, barcode scanner, color scanner, or microchip reader
- Indicator on the vial is read by the detector to determine formulation identity
- Device selects shaking rate and duration from pre-set options for each formulation type
- Activation is shaking-based using selected parameters
- Aqueous vs non-aqueous formulations are defined with the same lipid trio and different solvents
- Non-aqueous has <5% water (w/w)
- Pre-set options include shaking duration at least 30 seconds
2) Independent claim 12: similar but shifts structure to “first set/second set” with optional lookup logic
Claim 12 is narrower in how it states the system (vial + indicator placed in a device with controllers/processor; “first and second set” of activation parameters). It includes the same chemistry constraints and parameter floor: shaking time ≥30 seconds.
3) Independent claim 13: distinguishes aqueous vs non-aqueous by requiring different predetermined time/rate bands
Claim 13 requires:
- Reading vial indicator and distinguishing:
- non-aqueous requires activation for a first predetermined period ≥ about 30 seconds and/or first predetermined shaking rate ≥3000 motions/min
- aqueous requires a different period and/or a different shaking rate
- Activating the non-aqueous with the first time and/or first rate
- Detector options are the same four
- Non-aqueous has <5% water (w/w)
Practical infringement logic
Across claims 1/12/13/27/28, infringement is most sensitive to:
- Whether the system uses vial identification via indicator readable by the specified detector types
- Whether the shaking parameters are selected differently for aqueous vs non-aqueous formulations
- Whether the “non-aqueous” formulation meets the specific solvent and water constraints (<5% w/w water) and includes DPPA, DPPC, MPEG5000-DPPE
- Whether activation is performed via a shaking pattern with rates in the claimed ranges and durations of at least 30 seconds
What is the parameter envelope claimed (rates and durations)?
Below are the explicit parameter constraints as written:
| Claim |
Pre-set or first predetermined shaking duration |
Shaking rate limits |
Notes |
| 1 |
≥ 30 seconds |
selected from pre-set options |
independent; does not fix a single rate |
| 2 |
about 45 seconds |
≥ 4000 motions/min |
“one pre-set option” |
| 7 |
not specified |
≥ 4500 motions/min |
“one pre-set option” |
| 8 |
45 seconds |
4530 motions/min |
“one pre-set option” |
| 9 |
45 seconds |
about 4900 motions/min |
“another pre-set option” |
| 10 |
not specified |
not specified |
storage device stores look-up table of pre-sets |
| 13 |
first period ≥ about 30 seconds |
first rate ≥ 3000 motions/min |
explicit distinction between aqueous vs non-aqueous |
| 15 |
about 75 seconds |
not specified |
dependent on claim 13 |
| 16 |
about 75 seconds |
about 4530 motions/min |
dependent on claim 15 |
| 17 |
not specified |
≥ 4500 motions/min |
dependent on claim 13 |
| 18 |
not specified |
about 4900 motions/min |
dependent on claim 13 |
| 25 |
45 seconds |
about 4900 motions/min |
dependent on claim 13 |
| 26 |
not specified |
≥ 5000 motions/min |
dependent on claim 13 |
| 27 |
at least 30 seconds implied via claim 1 structure |
not specified |
non-aqueous with <5% water; detector options; indicator-based selection |
| 28 |
not specified |
not specified |
indicator provides method of use |
The “floor” for rates is claim-dependent
- General floor for non-aqueous distinction: ≥3000 motions/min (claim 13)
- Stronger floors in dependent claims: ≥4000 (claim 2), ≥4500 (claims 7, 17), ≥5000 (claim 26)
What is the device and workflow scope (what must the shaking apparatus do)?
The claims cover a shaking apparatus with functional components and optional structural features.
Functional requirements
The shaking device in the claims must include:
- holder for the vial
- detector that reads a vial indicator
- processor (and optionally controllers / controllers are in claim 12)
- logic to:
- identify the formulation (aqueous vs non-aqueous)
- select activation parameters from pre-set options or stored look-up tables
- activation by imparting a shaking pattern to the vial
Explicit device options and structure in dependent claims
| Claim |
Device feature |
Claim language effect on scope |
| 3 |
two or more holders |
expands to multi-vial systems |
| 5 |
battery |
portable/independent power not required for infringement unless combined in dependent claim |
| 6 |
holder fits 35 mm tall x 14.5 mm diameter vial |
strict dimensional design lock-in |
| 10 |
storage device with lookup table for pre-set options |
ties parameter selection to programmable device memory |
| 19 |
auto-selects first predetermined period from ≥2 options |
requires automated parameter switching |
| 20 |
auto-selects first predetermined shaking rate from ≥2 options |
requires automated parameter switching |
Detection modality scope
Infringement depends on whether the system uses a detector that falls within the explicitly listed categories:
- RFID reader/detector
- barcode scanner
- color scanner
- microchip reader
The claims do not list “imaging camera” or “machine vision” as a generic alternative; scope is anchored to these listed detector types.
What are the lipid and formulation constraints that narrow the claim scope?
Lipid trio is fixed in the claims that define composition
The claims (as provided) repeatedly constrain the formulations to:
Solvent system and water content are used as discriminators
The claims use two discriminators:
- Aqueous vs non-aqueous solvent
- Non-aqueous water constraint: less than 5% water (w/w)
Non-aqueous solvent composition is constrained to:
- propylene glycol and glycerol
How this affects design-around potential
From a landscape perspective, the claims place high value on avoiding the combination of:
- the specific lipid trio plus
- the non-aqueous solvent plus
- the water threshold (<5% w/w) plus
- indicator-based automated parameter selection.
A product that uses the same shaking concept but changes lipid identity or solvent/water profile likely exits the literal claim envelope for the formulation definitions in the independent claims.
How broad is the clinical/use portion of the claims?
The downstream steps are classic method-of-use content:
- administer microspheres to a subject
- obtain an ultrasound image
These are not parameterized beyond the upstream activation method, so the key patent differentiation is the formulation-specific, indicator-driven activation and the specific formulation definitions.
What does the dependent claim stack add to scope breadth?
Dependent claims primarily do two things:
- Pin activation parameters tightly (45 seconds, 75 seconds, 4530 rpm, 4900 rpm, ≥5000 rpm)
- Pin device design (multi-holder capability, battery, vial geometry)
This creates layered claim coverage:
- Independent claims capture the general method with indicator-based selection and formulation definitions.
- Dependent claims can be used as narrower fallbacks in litigation by emphasizing a particular shaking protocol or device configuration.
What is the patent landscape implication for competitors and investors?
Landscape risk focus
The most commercially relevant exposure is for companies building:
- lipid-encapsulated gas microspheres
- in a shaking/activation workflow
- where aqueous vs non-aqueous UCA lipid vials need different activation parameters
- with automated vial identity detection and selection
If those players already:
- use an RFID/barcode/color/microchip indicator, and
- program different shaking recipes based on that identity, and
- use DPPA/DPPC/MPEG5000-DPPE in the stated solvent systems,
then 10,588,988 is likely a central claim in infringement analyses.
Patent “hot spots” created by the claims
These are the points where most future design work will cluster:
- vial indicator format and detector choice (RFID vs barcode vs color vs microchip)
- activation recipe definition (pre-set duration, shaking rates, recipe switching logic)
- maintaining or avoiding the <5% water condition in the non-aqueous formulation
- maintaining the solvent composition (propylene glycol/glycerol) and lipid trio
Likely validity and prosecution leverage (based on claim structure alone)
The claim structure is engineered as a “closed loop”:
- it ties identity detection to pre-set activation selection,
- ties activation selection to a specific composition/solvent profile,
- and then ties the resulting product and imaging outcome to the method steps.
This can reduce the chance that prior art covers a partially overlapping workflow without matching the formulation identity discrimination and the activation-parameter selection.
How should you map 10,588,988 against a product spec? (Claim-to-spec checklist)
To determine whether a product or process sits inside or outside the claim scope, map the following:
- Does the method include reading a vial indicator with one of these detector types?
- RFID / barcode / color / microchip
- Does the device distinguish aqueous vs non-aqueous formulations based on that indicator?
- Does it select different shaking rate and shaking duration pre-sets for the identified formulation?
- Is activation done by imparting a shaking pattern to the vial?
- Do the formulations contain DPPA + DPPC + MPEG5000-DPPE?
- For non-aqueous: is solvent propylene glycol + glycerol, and water content <5% w/w?
- Do shaking durations meet at least 30 seconds?
- Are shaking rates at least 3000 motions/min for the non-aqueous recipe (and higher if practicing dependents)?
- Is the microsphere suspension administered to a subject and imaged by ultrasound?
Passing all of these is the literal-claim pathway for independent claims 1/12/13/27.
Key Takeaways
- 10,588,988 is a method-of-use and workflow patent focused on indicator-driven, formulation-specific shaking activation to produce lipid-encapsulated gas microspheres for ultrasound imaging.
- The claims tightly constrain composition (DPPA, DPPC, MPEG5000-DPPE) and non-aqueous solvent/water (propylene glycol/glycerol; <5% water w/w).
- The largest commercial leverage is in automation: reading vial identity via RFID/barcode/color/microchip and selecting pre-set shaking recipes with durations ≥30 seconds and non-aqueous rates ≥3000 motions/min (often ≥4000 to ~5000 in dependent claims).
- Dependent claims lock key commercial protocols into 45 seconds, 75 seconds and shaking rates around 4530 and 4900 motions/min, creating litigation fallback positions.
FAQs
-
What distinguishes 10,588,988 from generic ultrasound contrast imaging patents?
It is centered on the mechanical activation workflow that varies shaking parameters based on vial identity read by a detector.
-
Are the claimed activation parameters required for infringement?
Yes. The independent claims require selecting a shaking rate and duration from pre-set options and performing shaking activation; dependent claims narrow those values further.
-
Does the patent cover only RFID systems?
No. It covers RFID readers/detectors plus barcode scanners, color scanners, and microchip readers as the detector category.
-
How narrow is the formulation scope?
The claims define both aqueous and non-aqueous UCA lipid formulations with the lipid trio DPPA, DPPC, MPEG5000-DPPE, and require non-aqueous solvent propylene glycol + glycerol with <5% water (w/w).
-
Where is the strongest design-around lever?
Changing the formulation definitions (lipid trio and/or non-aqueous solvent/water profile) and/or avoiding the indicator-read detector/automated recipe selection are the primary levers against literal claim coverage.
References
- United States Patent No. 10,588,988.
